:format(webp))
These groundbreaking medical innovations require a monumental shift in how global supply chains operate. Transporting living, perishable biological materials across borders, with no margin for error, demands an entirely new playbook.
Michael Sweeney, QuickSTAT’s Global Head of Strategy for CGT & DTP, shares expert perspectives on navigating the frontiers of advanced therapeutics.
Learn why the global logistics ecosystem must keep pace with medical innovation through early strategic planning that secures the pathway from clinical success to commercial reality.
How QuickSTAT synchronizes the entire chain of custody, from the initial collection of a patient's cells at a clinical site to manufacturing and back to the hospital for infusion.
The critical steps required to transition a highly sensitive supply chain from small-scale clinical trial phases to robust, high-volume commercial distribution.
A look at the advanced cold chain solutions and ultra-fast routing strategies used to preserve the viability of living cells that must remain frozen at cryogenic temperatures.
How specialised logistics teams map out alternative lanes and build redundancies into shipping plans to bypass customs delays or transit disruptions.
Loading iFrame
Press play to get started.
Because advanced therapies are often created using a patient's own cells, a single logistics failure means a patient may lose their only chance at
treatment.
Years of research and financial investments rely entirely on the final transport phase. Flawless execution ensures that the medicine arriving at the bedside matches the laboratory’s exact quality.
Integrating supply chain design into early-stage clinical trial development allows developers to identify and eliminate vulnerabilities before scaling globally.